Darlene Dobkowski, MA

Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid cancer and breast cancer.

In addition to increased treatment costs, patients with head and neck cancers also experienced therapy changes during the cisplatin shortage.

The approval of Retevmo is for the treatment of adults and children aged 2 years and older with advanced or metastatic medullary thyroid cancer.

The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Through communication and education, patients with metastatic breast cancer may be able to balance treatment with quality of life.

Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit from this treatment.

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial.

An artificial intelligence model was shown to predict tumor mutation burden in lung cancer and other diseases.

At the 2024 ESMO Congress, an expert explained how Nubeqa may reduce fatigue-related side effects in metastatic hormone-sensitive prostate cancer.

Hypofractionated radiation was noninferior to normofractionated radiation in patients with early breast cancer regarding lymphedema risk.

High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or death with Herceptin treatment.

Rybrevant plus chemotherapy improved overall survival versus chemo alone in EGFR-mutant advanced non-small cell lung cancer after disease progression.

Several drug classes, including immunotherapy, antibody-drug conjugates and PARP inhibitors have helped improve outcomes for gynecologic cancers.

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers.

Spleen size, blood counts and symptom burden are some of the factors cancer teams take into account when selecting which of the four JAK inhibitors to treat patient with myelofibrosis.

An expert explained the importance of understanding different subtypes of metastatic breast cancer and available treatment options based on biomarker testing.

Join us for an Educated Patient® Webinar to explore the essential aspects of radiotherapy as a treatment for cancer, in addition to its various types and practical advice on managing side effects.

The FDA will review an application for Cabometyx as a potential treatment for pancreatic neuroendocrine tumors after findings from a phase 3 trial.

Actress Shannen Doherty has been open about her experience with breast cancer over the last few years as a way to help other people.

Increased awareness and support may be one of the many ways to help decrease the impact of disparities in multiple myeloma.

An artificial intelligence-based navigation tool may be used to call patients who previously missed their colonoscopy appointment with the goal that they will reschedule and attend the new appointment.

During this in-person event, over 500 attendees celebrated the remarkable efforts made by oncology nurses in the care of patients with cancer.

In collaboration with the Kidney Cancer Association, CURE® recently hosted the “Educated Patient® Webinar: Treating the Whole Patient: Navigating Kidney Cancer,” hosted by Darlene Dobkowski, Associate Editorial Director for CURE®.

During the CURE Educated Patient® Breast Cancer Summit, an expert discussed her professional and personal experience with side effect management in metastatic breast cancer.

A patient advocate and oncology nurse discuss the importance of physical and mental health during the breast cancer journey during a panel session at the CURE® Educated Patient® Breast Cancer Summit.

An oncology nurse discusses how virtual reality can be used to educate patients and decrease stress before treatment or while in palliative care.

Researchers have initiated a phase 2 trial assessing a novel tyrosine kinase inhibitor that can potentially penetrate the central nervous system in patients with ALK-positive non-small cell lung cancer and other solid tumors.

A 2.5-mg dose of olanzapine provided similar control of nausea/vomiting as the standard 10-milligram dose in patients with solid tumors receiving chemotherapy.

Nubeqa plus androgen deprivation therapy and docetaxel to treat patients with metastatic hormone-sensitive prostate cancer lowered hospitalization rates but led to marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy and docetaxel.

This study assessed the impact of laughter therapy in both patients with cancer and caregivers, and both groups showed decreases in mood disturbances, in addition to decreases in pain for patients and in burnout for caregivers.